Compounding Bill In Senate Adds Office Use Provisions
This article was originally published in The Pink Sheet Daily
Executive Summary
New version of compounding bill would allow compounders to produce limited supplies for office use, but schedule for Senate floor action remains to be seen.
You may also be interested in...
Makena’s Orphan Exclusivity Is “Nullified” By FDA’s Compounding Policy, KV Suit Says
KV seeks a court order requiring FDA to desist from permitting importation of unapproved API for compounded hydroxyprogesterone and to state its intent to take enforcement action against compounders.
Could US FDA Move Gene Therapy Regulation To Device Center In Years To Come?
CBER Director Peter Marks said more sophisticated manufacturing expected in the next decade could lead to questions about whether gene therapies should be regulated by his center or CDRH.
US FDA Implementing Hybrid Work Policy In January
Agency employees will have on-site, telework and remote possibilities, but options will depend on the center, office and job duties.